Views:0 Author:Site Editor Publish Time: 2021-03-04 Origin:Site
Selectivity changes imparted by sulfobutyl ether beta-cyclodextrin (SBECD) modifier were evaluated in reversed phase HPLC separations. The mixed mode capabilities of SBECD, including cation exchange and an orthogonal hydrophobic interaction (i.e., via inclusion complex), altered the typical retention properties of a C18 column.
This enabled several racemates (fenoterol, idazoxan hydrolyzate, orciprenaline, terbutaline, tranylcypromine, and imazalil) to be resolved. The selectivity of SBECD is distinct, as the related sulfated beta-cyclodextrin (SCD) modifier separated different racemates (1-aminoindane, fenoterol, both idazoxan and its hydrolyzate, nefopam, terbutaline, and tranylcypromine).
The SBECD modifier also improved main peak resolution or altered impurity profiles for the fermentation-derived drug substances A40926, ramoplanin, teicoplanin, and vancomycin. Selectivity changes from SBECD were shown to be beneficial for chiral and chemical purity separations.
Moreover, cyclodextrin modifier may enable a combined chiral and overall chemical purity method to be developed, which is not feasible by only using current chiral or reversed phase C18 columns alone. This study demonstrated that cyclodextrins and their derivatives are underutilized for HPLC and warrant consideration as a viable alternative to commercially available chiral or mixed mode columns.